Buprenorphine

Major

Buprenorphine Imipramine Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Indapamide Explained Reduced efficacy of diuretics Details Buprenorphine Indinavir Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Inotuzumab Ozogamicin Besponsa Explained An increased risk of QT interval prolongation Details Buprenorphine Ipratropium Explained An increased risk of paralytic ileus Details Buprenorphine Isoflurane Fluriso Explained An increased risk of respiratory depression, an increased risk of CNS depression, reduced isoflurane (MAC) exposure and an increas... Details Buprenorphine Itraconazole Sporanox Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Ivabradine Corlanor An increased risk of QT interval prolongation Details Buprenorphine Ivacaftor Kalydeco Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Ivosidenib Tibsovo Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Buprenorphine Ketamine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ketazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Ketobemidone Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Kratom Explained Increased CYP3A substrate exposure, increased risk of CNS depression and serotonin syndrome Details Buprenorphine Lacosamide Motpoly Explained An increased risk of CNS depression Details Buprenorphine Lapatinib Tykerb Explained An increased risk of QT interval prolongation Details Buprenorphine Larotrectinib Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Lasmiditan Reyvow Explained Increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Buprenorphine Lefamulin Xenleta Increased risk of QT interval prolongation Details Buprenorphine Lemborexant Dayvigo Explained An increased risk of CNS depression and potential next-day somnolence Details Buprenorphine Lenacapavir Sunlenca Explained Increased or reduced buprenorphine exposure Details Buprenorphine Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Buprenorphine Lesinurad Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Letermovir Prevymis Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Leuprolide Eligard Explained An increased risk of QT interval prolongation Details Buprenorphine Levocetirizine Xyzal Explained Increased risk of CNS depression Details Buprenorphine Levodopa Inbrija Explained An increased risk of CNS depression Details Buprenorphine Levofloxacin Levaquin An increased risk of QT interval prolongation Details Buprenorphine Levomilnacipran Explained An increased risk of serotonin syndrome Details Buprenorphine Levorphanol Xyvona Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Linezolid Zyvox Explained An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Lisdexamfetamine Arynta Explained An increased risk of serotonin syndrome Details Buprenorphine Lithium Explained Increased risk of serotonin syndrome Details Buprenorphine Lofepramine Explained An increased risk of serotonin syndrome Details Buprenorphine Lofexidine Explained Increased risk of CNS depressant effects and increased risk of QT interval prolongation Details Buprenorphine Lomitapide Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Lonafarnib Zokinvy Explained Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details Buprenorphine Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Buprenorphine Loprazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Lorazepam Ativan Explained An increased risk of CNS depression and respiratory depression Details